The Technical AnalystExchange: WSE Sector: Healthcare Industry: Biotechnology
BIOTON S.A. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.28% PLN3.55
America/New_York / 17 mai 2024 @ 11:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 304.82 mill |
| EPS: | 0.0300 |
| P/E: | 118.33 |
| Earnings Date: | Aug 27, 2024 |
| SharesOutstanding: | 85.86 mill |
| Avg Daily Volume: | 0.0330 mill |
| RATING 2024-05-17 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Neutral | |
| P/E: | Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 5.56x |
| Company: PE 118.33 | sector: PE 21.29 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 9.67x |
| Company: PE 118.33 | industry: PE 12.24 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
PLN2.06 (-41.96%) PLN-1.489 |
| Date: 2024-05-19 |
| Expected Trading Range (DAY) |
|---|
|
PLN 3.50 - 3.60 ( +/- 1.44%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | PLN3.55 (0.28% ) |
| Volume | 0.0127 mill |
| Avg. Vol. | 0.0330 mill |
| % of Avg. Vol | 38.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BIO.WA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BIO.WA
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, medications, and other pharmaceutical products in Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. The company offers recombinant human and classic insulin; oral anti-diabetic medication products; dietary supplements; strips for measuring sugar in blood, as well as OTC preparation for diabetics; diabetics drugs insulin vials and cartridges, including Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. It engages in advertising, advisory, and company management activities. The company was founded in 1989 and is based in Ozarów Mazowiecki, Poland.